KLST/Kallistatin Polyclonal Antibody
Applications
Reactivity
Predicted Reactivity
| Overview | |
| Catalog # | bs-5786R |
| Product Name | KLST/Kallistatin Polyclonal Antibody |
| Applications |
WB
ELISA
IHC-P
IHC-F
IF(IHC-P)
IF(IHC-F)
IF(ICC)
|
| Reactivity | Mouse |
| Predicted Reactivity | Human, Rat |
| Specifications | |
| Conjugation | Unconjugated |
| Host | Rabbit |
| Source | KLH conjugated synthetic peptide derived from human KLST/Kallistatin (161-220aa) |
| Immunogen Range | 151-250/427 |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| Target | |
| Gene ID | 5267 |
| Subcellular location | Secreted |
| Synonyms | Serpin peptidase inhibitor clade A member 4; Kallikrein binding protein; Kallikrein inhibitor; Protease inhibitor 4; Serpin A4; KAL; Kallikrein binding protein; Kallikrein inhibitor; KBP; KLST; KST; MGC108582; PI4; Protease inhibitor 4; Serpin A4; Serpin peptidase inhibitor clade A member 4; SERPINA4; KAIN_HUMAN. |
| Background | Kallistatin is a serine proteinase inhibitor which binds to tissue kallikrein and inhibits its amidolytic and kininogenase activity. Inhibition is achieved by formation of an equimolar, heat- and SDS-stable complex between the inhibitor and the enzyme, and generation of a small C-terminal fragment of the inhibitor due to cleavage at the reactive site by tissue kallikrein. Heparin blocks kallistatin's complex formation with tissue kallikrein and abolishes its inhibitory effect on tissue kallikrein's activity. |
| Application Dilution | |
| WB | 1:300-5000 |
| ELISA | 1:500-1000 |
| IHC-P | 1:200-400 |
| IHC-F | 1:100-500 |
| IF(IHC-P) | 1:50-200 |
| IF(IHC-F) | 1:50-200 |
| IF(ICC) | 1:50-200 |